Table of Contents
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Medication Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Market Analysis by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Overview of Global Benign Prostatic Hyperplasia (BPH) Medication Market
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Astellas Pharma Details
2.1.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Pharma SWOT Analysis
2.1.4 Astellas Pharma Product and Services
2.1.5 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Valeant Pharmaceuticals
2.2.1 Valeant Pharmaceuticals Details
2.2.2 Valeant Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Valeant Pharmaceuticals SWOT Analysis
2.2.4 Valeant Pharmaceuticals Product and Services
2.2.5 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bristol-Myers Squibb SWOT Analysis
2.5.4 Bristol-Myers Squibb Product and Services
2.5.5 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GlaxoSmithKline SWOT Analysis
2.6.4 GlaxoSmithKline Product and Services
2.6.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Foresee Pharmaceuticals
2.7.1 Foresee Pharmaceuticals Details
2.7.2 Foresee Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Foresee Pharmaceuticals SWOT Analysis
2.7.4 Foresee Pharmaceuticals Product and Services
2.7.5 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bayer HealthCare
2.8.1 Bayer HealthCare Details
2.8.2 Bayer HealthCare Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bayer HealthCare SWOT Analysis
2.8.4 Bayer HealthCare Product and Services
2.8.5 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 ADC Therapeutics
2.9.1 ADC Therapeutics Details
2.9.2 ADC Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 ADC Therapeutics SWOT Analysis
2.9.4 ADC Therapeutics Product and Services
2.9.5 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Endo Pharmaceuticals
2.10.1 Endo Pharmaceuticals Details
2.10.2 Endo Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Endo Pharmaceuticals SWOT Analysis
2.10.4 Endo Pharmaceuticals Product and Services
2.10.5 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Urologixs
2.11.1 Urologixs Details
2.11.2 Urologixs Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Urologixs SWOT Analysis
2.11.4 Urologixs Product and Services
2.11.5 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 BHR Pharma
2.12.1 BHR Pharma Details
2.12.2 BHR Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 BHR Pharma SWOT Analysis
2.12.4 BHR Pharma Product and Services
2.12.5 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Merck
2.13.1 Merck Details
2.13.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Merck SWOT Analysis
2.13.4 Merck Product and Services
2.13.5 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Sanpower Group
2.14.1 Sanpower Group Details
2.14.2 Sanpower Group Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Sanpower Group SWOT Analysis
2.14.4 Sanpower Group Product and Services
2.14.5 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Agennix
2.15.1 Agennix Details
2.15.2 Agennix Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Agennix SWOT Analysis
2.15.4 Agennix Product and Services
2.15.5 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Teva Pharmaceutical Industries
2.16.1 Teva Pharmaceutical Industries Details
2.16.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Teva Pharmaceutical Industries SWOT Analysis
2.16.4 Teva Pharmaceutical Industries Product and Services
2.16.5 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Novartis
2.17.1 Novartis Details
2.17.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Novartis SWOT Analysis
2.17.4 Novartis Product and Services
2.17.5 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 Boehringer Ingelheim
2.18.1 Boehringer Ingelheim Details
2.18.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Boehringer Ingelheim SWOT Analysis
2.18.4 Boehringer Ingelheim Product and Services
2.18.5 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 ANI Pharmaceuticals
2.19.1 ANI Pharmaceuticals Details
2.19.2 ANI Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 ANI Pharmaceuticals SWOT Analysis
2.19.4 ANI Pharmaceuticals Product and Services
2.19.5 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.20 Advaxis
2.20.1 Advaxis Details
2.20.2 Advaxis Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Advaxis SWOT Analysis
2.20.4 Advaxis Product and Services
2.20.5 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.21 Spectrum Pharmaceuticals
2.21.1 Spectrum Pharmaceuticals Details
2.21.2 Spectrum Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Spectrum Pharmaceuticals SWOT Analysis
2.21.4 Spectrum Pharmaceuticals Product and Services
2.21.5 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.22 Eisai
2.22.1 Eisai Details
2.22.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Eisai SWOT Analysis
2.22.4 Eisai Product and Services
2.22.5 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.23 Nymox Pharmaceutical
2.23.1 Nymox Pharmaceutical Details
2.23.2 Nymox Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Nymox Pharmaceutical SWOT Analysis
2.23.4 Nymox Pharmaceutical Product and Services
2.23.5 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.24 Madrigal Pharmaceuticals
2.24.1 Madrigal Pharmaceuticals Details
2.24.2 Madrigal Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Madrigal Pharmaceuticals SWOT Analysis
2.24.4 Madrigal Pharmaceuticals Product and Services
2.24.5 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.25 LIDDS
2.25.1 LIDDS Details
2.25.2 LIDDS Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 LIDDS SWOT Analysis
2.25.4 LIDDS Product and Services
2.25.5 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.26 Ferring
2.26.1 Ferring Details
2.26.2 Ferring Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Ferring SWOT Analysis
2.26.4 Ferring Product and Services
2.26.5 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.27 Takeda Pharmaceuticals
2.27.1 Takeda Pharmaceuticals Details
2.27.2 Takeda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.27.3 Takeda Pharmaceuticals SWOT Analysis
2.27.4 Takeda Pharmaceuticals Product and Services
2.27.5 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.28 IO THERAPEUTICS
2.28.1 IO THERAPEUTICS Details
2.28.2 IO THERAPEUTICS Major Business and Total Revenue (Financial Highlights) Analysis
2.28.3 IO THERAPEUTICS SWOT Analysis
2.28.4 IO THERAPEUTICS Product and Services
2.28.5 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Medication Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.5 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
5.2 United States Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.3 UK Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.4 France Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Regions (2015-2020)
7.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.5 India Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
7.7 Australia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.3 Turkey Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
9.5 South Africa Benign Prostatic Hyperplasia (BPH) Medication Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales and Market Share by Type (2015-2020)
10.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2015-2020)
10.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2015-2020)
11 Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2015-2020)
11.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2015-2020)
11.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2015-2020)
12 Market Forecast
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Growth Rate (2021-2025)
12.2 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Regions (2021-2025)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.2.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Forecast (2021-2025)
12.3 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Type (2021-2025)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2021-2025)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Type (2021-2025)
12.4 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Application (2021-2025)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2021-2025)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
【免責事項】
https://www.globalresearch.jp/disclaimer